Bristol-Myers Squibb & Co BMY announced its ambitious plan to double the number of treatments undergoing clinical trials in the next 18 months, focusing primarily on targeted protein degradation and cell therapies.
The pharmaceutical giant currently has six candidates in various trial phases and intends to advance an additional six in its research pipeline. Among these, three are cell therapies designed to address immune system disorders and various cancer types.
Bristol-Myers Squibb’s two leading drugs, cancer treatment Revlimid and the blood thinner Eliquis face generic competition.
Eliquis is one of the 10 drugs set to undergo price negotiations within the U.S. Medicare health program.
The company is expanding its manufacturing capacity, exploring innovative technologies such as dual-targeting CARs and allogenic approaches, and advancing multiple next-generation assets, including new targets. Bristol-Myers Squibb is also rapidly expanding into immunology, including lupus and multiple sclerosis.
The company already has two approved cell therapies in the U.S., Breyanzi (lisocabtagene maraleucel) and Abecma (idecabtagene vicleucel), targeting different blood cancer indications.
BMY Price Action: Bristol-Myers Squibb shares are down 0.42% at $59.41 on the last check Thursday.
Read Next: Moderna’s R&D Day Unveils Strategic Roadmap Beyond COVID Franchise: Goldman Sachs
